Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Key Inclusion Criteria: * Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures * Adult males and non-pregnant, non-lactating females * Documented evidence of chronic HBV infection with detectable hepatitis B surface antigen (HBsAg) levels * On commercially available HBV OAV treatment(s) for at least 6 months with no change in regimen for 3 months prior to screening * HBV Deoxyribonucleic acid (DNA) ≤ 20 IU/mL for 6 or more months prior to screening * Screening Electrocardiogram (ECG) without clinically significant abnormalities Key Exclusion Criteria: * Extensive bridging fibrosis or cirrhosis * Adults meeting any of the protocol defined exclusionary laboratory parameters at screening: * Alanine aminotransferase (ALT) \> 3x Upper Limit of Normal (ULN) * International normalized ratio (INR) \> ULN unless the adult is stable on an anticoagulant regimen * Albumin \< 3.5 g/dL * Direct bilirubin \> 1.5x ULN * Platelet Count \< 100,000/uL * Estimated creatinine clearance \< 60 mL/min (using the Cockcroft-Gault method) * Co-infection with human immunodeficiency virus, hepatitis C virus or hepatitis D virus * Prior history of hepatocellular carcinoma (HCC) or screening alpha-fetoprotein ≥ 50 ng/mL without imaging * Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease, hemoglobinopathy, retinal disease, or are immunosuppressed. * Chronic liver disease of a non-HBV etiology, except for non-alcoholic fatty liver disease * Received solid organ or bone marrow transplant * Received prolonged therapy with immunomodulators or biologics within 3 months of screening * Use of another investigational agent within 90 days of screening, unless allowed by the Sponsor NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.